Business Context and Reporting Period
Aclaris Therapeutics, Inc. (ACRS), a Delaware corporation, filed this Form 8-K on March 10, 2026. The report discloses a specific equity financing event under Item 7.01 (Regulation FD Disclosure).
Key Financial Metrics
This filing reports a discrete capital raise rather than periodic financial performance metrics.
- Gross Proceeds: $20.0 million
- Shares Sold: 5.7 million shares of common stock
- Implied Price per Share: Approximately $3.51
- Transaction Type: At-the-market sale pursuant to an amended and restated sales agreement dated February 27, 2025.
The filing does not provide data on revenue, profit, operating cash flow, margins, debt levels, or overall liquidity positions.
Material Changes
The material change reported is the issuance of 5.7 million shares of common stock. The shares were purchased by Frazier Life Sciences, Kalehua Capital, and Adage Capital Partners LP. This transaction increases the company's cash position by $20.0 million and increases the number of outstanding shares.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the information in Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the updated total number of outstanding shares following the issuance of 5.7 million new shares.
- Confirm the use of proceeds from the $20.0 million raise in subsequent filings or press releases.
- Review the terms of the sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co. to understand ongoing at-the-market selling capabilities.
- Check for any dilution impact on existing shareholders given the new share issuance.